Drug Profile
Research programme: adoptive T-cell therapy - Tactiva Therapeutics
Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Roswell Park Cancer Institute; Tactiva Therapeutics
- Developer Tactiva Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte stimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 26 Nov 2018 Tactiva Therapeutics plans phase I/IIa TACT-001 trial for Solid tumours, including ovarian cancer, prostate cancer, pancreatic cancer, non-small cell lung cancer and melanoma in 2019
- 26 Nov 2018 Tactiva Therapeutics plans a clinical trial for Multiple myeloma in 2019